Sp1 Formula

Dosage for Phytolacca Americana Root extract is highly individualized and must be determined through a 'dose-titration' method.

• Initial Phase: Typically starts with a very low concentration (e.g., 0.01 mL to 0.05 mL of a 1:100,000 w/v dilution).
• Maintenance Phase: Doses are gradually increased over weeks or months until a maintenance dose is reached, often ranging from 0.1 mL to 0.5 mL of a 1:100 w/v or 1:10 w/v concentration.

Phytolacca Americana Root allergenic extracts are not generally recommended for children under the age of 5. For older children, dosing is adjusted based on body weight and the severity of the allergic sensitivity, following the same titration principles as adults.

Renal Impairment

No specific dosage adjustments are provided for renal impairment; however, caution is advised as systemic clearance may be slowed.

Hepatic Impairment

No specific data exists for hepatic adjustment, but clinicians should monitor for systemic toxicity in patients with severe liver disease.

Elderly Patients

Elderly patients may have a higher risk of cardiovascular complications if a systemic reaction occurs. Dosing should be conservative, starting at the lowest possible concentration.

• Administration: This medication must be administered by a trained healthcare professional in a clinical setting equipped with emergency resuscitation equipment.
• Observation: Patients must remain in the clinic for at least 30 minutes following an injection to monitor for signs of anaphylaxis.
• Storage: Store the extract in a refrigerator between 2°C and 8°C (36°F to 46°F). Do not freeze.

If a dose is missed during the build-up phase, the next dose may need to be reduced to ensure safety. If the maintenance phase is interrupted for more than two weeks, consult your allergist, as the dose may need to be stepped back to a previous level.

Signs of overdose (or accidental systemic injection) include hives, swelling of the throat, difficulty breathing, and hypotension (low blood pressure). Immediate administration of epinephrine is required in the event of a systemic reaction.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

• Local Injection Site Reactions: Redness, itching, and swelling at the site of injection. These typically resolve within 24 to 48 hours.
• Mild Congestion: Temporary worsening of nasal symptoms following the injection.

• Large Local Reactions: Swelling larger than 5 cm at the injection site, which may be treated with cold compresses and antihistamines.
• Fatigue: A general feeling of tiredness or malaise shortly after treatment.
• Headache: Mild to moderate tension-type headaches.

• Generalized Urticaria: Hives appearing on parts of the body away from the injection site.
• Gastrointestinal Distress: Nausea or abdominal cramping, potentially indicating a systemic response.

> Warning: Stop taking Phytolacca Americana Root and call your doctor immediately if you experience any of these.

• Anaphylaxis: A life-threatening allergic reaction involving multiple organ systems.
• Angioedema: Severe swelling of the lips, tongue, or throat that can obstruct the airway.
• Wheezing or Dyspnea: Difficulty breathing or a tight chest.
• Hypotension: A sudden drop in blood pressure leading to dizziness or fainting.

Prolonged use in immunotherapy is generally well-tolerated. However, some patients may develop 'serum sickness-like' symptoms, including joint pain and fever, though this is exceedingly rare with modern extracts.

WARNING: RISK OF SEVERE ALLERGIC REACTION

Phytolacca Americana Root extracts can cause severe, life-threatening systemic allergic reactions, including anaphylaxis. This medication should only be administered by healthcare providers experienced in the treatment of anaphylaxis. Patients with unstable asthma or those taking beta-blockers may be at increased risk of severe outcomes.

Report any unusual symptoms to your healthcare provider.

Phytolacca Americana Root extract is a potent biological agent. It must never be self-administered. Patients must be screened for existing sensitivities and current health status before every injection.

According to FDA standards for allergenic extracts, a black box warning is required regarding the risk of Anaphylaxis. The extract must be administered in a facility where emergency medications (epinephrine, oxygen, IV fluids) and trained personnel are immediately available.

• Allergic Reactions / Anaphylaxis Risk: The primary risk is a systemic allergic reaction. This is more common during the 'build-up' phase of treatment.
• Asthma Exacerbation: Patients with poorly controlled asthma should not receive immunotherapy until their condition is stabilized, as they are at higher risk for fatal bronchospasm.
• Cardiovascular Risk: Patients with pre-existing heart disease may not tolerate the stress of a systemic reaction or the effects of epinephrine used to treat such a reaction.

• Peak Flow Monitoring: For asthmatic patients, peak flow should be checked before each injection.
• Visual Inspection: The injection site must be inspected for 30 minutes post-dose.
• Vital Signs: Blood pressure and heart rate monitoring may be necessary for high-risk patients.

Patients should use caution when driving or operating machinery immediately after an injection, as some individuals experience dizziness or fatigue.

Alcohol should be avoided on the day of the injection, as it can increase vasodilation and potentially accelerate the onset of a systemic allergic reaction.

If a patient experiences a severe systemic reaction, the healthcare provider may decide to discontinue the therapy or significantly reduce the dose. There is no withdrawal syndrome associated with stopping allergenic extracts.

> Important: Discuss all your medical conditions with your healthcare provider before starting Phytolacca Americana Root.

• Beta-Blockers: Drugs like propranolol or metoprolol are contraindicated because they can block the effects of epinephrine, making it difficult to treat a systemic reaction or anaphylaxis.

• MAO Inhibitors (MAOIs): Medications used for depression (e.g., phenelzine) can potentiate the effects of sympathomimetics, complicating the treatment of an allergic reaction.
• Tricyclic Antidepressants: Similar to MAOIs, these can increase the cardiovascular risks if epinephrine is administered.

• Other Immunotherapy: Receiving multiple different allergenic extracts simultaneously increases the cumulative risk of a systemic reaction.
• Antihistamines: While often used to treat side effects, they can mask the early warning signs of a serious systemic reaction.

• High-Fat Meals: No direct interaction with the extract, but heavy meals may complicate the management of gastrointestinal symptoms during a systemic reaction.
• Alcohol: As noted, alcohol can increase the risk of a severe reaction by altering vascular permeability.

• St. John's Wort: May interact with the metabolic pathways of the various MoAs (like Estrogen Receptor Agonism) listed for this extract.
• Ginkgo Biloba: May increase bleeding risk at the injection site due to its anti-platelet effects.

• Skin Tests: Phytolacca Americana Root will interfere with future skin prick tests for other allergens if the patient is currently in the build-up phase of immunotherapy.
• IgE Testing: Total and specific IgE levels may fluctuate during treatment.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Severe, Uncontrolled Asthma: Patients with a forced expiratory volume (FEV1) consistently below 70% of predicted values should not receive this extract due to the risk of fatal bronchospasm.
• Recent Myocardial Infarction: Patients who have had a heart attack within the last 3-6 months are at extreme risk if a systemic reaction occurs.
• Hypersensitivity to Diluents: Patients allergic to phenol (a common preservative in extracts) must not use this product.

• Autoimmune Disorders: Patients with active autoimmune diseases may experience a flare-up of their condition due to the immune-stimulating effects of the extract.
• Malignancy: Immunotherapy is generally avoided in patients with active cancer unless the benefits clearly outweigh the risks.

Patients allergic to other members of the Phytolaccaceae family may exhibit cross-reactivity. There is also anecdotal evidence of cross-sensitivity with certain latex proteins, though clinical data is limited.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Phytolacca Americana Root.

Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. While immunotherapy is generally not started during pregnancy, maintenance doses may be continued if the benefit to the mother outweighs the risk to the fetus. The primary risk is maternal anaphylaxis, which can cause fetal hypoxia (lack of oxygen).

It is not known whether the components of Phytolacca Americana Root extract pass into breast milk. Because many proteins are digested in the infant's gut, the risk is considered low, but caution should be exercised.

Safety and effectiveness in children under the age of 5 have not been established. In older children, the risk of systemic reactions is similar to that in adults, but communication of early symptoms may be more difficult.

Patients over 65 may have a higher prevalence of cardiovascular disease, making them more vulnerable to the effects of a systemic reaction. Careful evaluation of the heart and lung function is required before starting therapy.

Specific dosing for patients with kidney failure has not been studied. Clearance of the biological components may be delayed, necessitating a slower dose escalation.

No specific adjustments are recommended, but patients with liver failure should be monitored for signs of systemic toxicity, as the liver plays a role in processing circulating proteins.

> Important: Special populations require individualized medical assessment.

Phytolacca Americana Root extract works primarily as an immunomodulator. It acts on Estrogen Receptor Agonists [MoA] and Corticosteroid Hormone Receptor Agonists [MoA], which may contribute to its anti-inflammatory and mitogenic properties. By stimulating T-lymphocytes via pokeweed mitogen (PWM), it alters the cytokine environment, reducing the production of IL-4 and IL-5 (pro-allergic cytokines) and increasing IFN-gamma.

The onset of action for diagnostic testing is rapid (15-30 minutes). For immunotherapy, the therapeutic effect (reduction in allergy symptoms) typically takes 6 to 12 months of consistent treatment. Tolerance develops through the induction of T-regulatory cells.

| Parameter | Value |

|---|---|

| Bioavailability | Low (Subcutaneous) |

| Protein Binding | Variable (Albumin-bound) |

| Half-life | Not established for extract |

| Tmax | 1-2 hours (Systemic absorption) |

| Metabolism | Proteolysis (Tissue/Liver) |

| Excretion | Renal/Lymphatic |

• Molecular Formula: Complex mixture of proteins, glycoproteins, and saponins.
• Molecular Weight: Ranges from 10 kDa to over 100 kDa for various protein fractions.
• Solubility: Soluble in aqueous buffered solutions containing 0.5% phenol.

Phytolacca Americana Root is classified as a Non-Standardized Plant Allergenic Extract [EPC]. It is related to other plant extracts like Ragweed or Timothy Grass used in allergy desensitization.